These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10560800)

  • 21. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
    Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
    Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics during continuous haemofiltration.
    Bressolle F; Kinowski JM; de la Coussaye JE; Wynn N; Eledjam JJ; Galtier M
    Clin Pharmacokinet; 1994 Jun; 26(6):457-71. PubMed ID: 8070219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of continuous renal replacement therapy.
    Schetz M; Ferdinande P; Van den Berghe G; Verwaest C; Lauwers P
    Intensive Care Med; 1995 Jul; 21(7):612-20. PubMed ID: 7593908
    [No Abstract]   [Full Text] [Related]  

  • 24. Extended Daily Dialysis Versus Continuous Renal Replacement Therapy for Acute Kidney Injury: A Meta-analysis.
    Zhang L; Yang J; Eastwood GM; Zhu G; Tanaka A; Bellomo R
    Am J Kidney Dis; 2015 Aug; 66(2):322-30. PubMed ID: 25843704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetics of antibiotics in continuous renal replacement therapies (CRRT)].
    Morabito S; Pistolesi V; Maggiore U; Fiaccadori E; Pierucci A
    G Ital Nefrol; 2012; 29(4):425-44. PubMed ID: 22843155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug dosing in continuous renal replacement therapy: general rules.
    Schetz M
    Curr Opin Crit Care; 2007 Dec; 13(6):645-51. PubMed ID: 17975384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Continuous renal replacement therapies (CRRT)].
    Canepari G; Inguaggiato P; Gigliola G; Bainotti S; Formica M
    G Ital Nefrol; 2006; 23 Suppl 36():S30-7. PubMed ID: 17068727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acid-base balance and replacement solutions in continuous renal replacement therapies.
    Feriani M; Dell'Aquila R
    Kidney Int Suppl; 1998 May; 66():S156-9. PubMed ID: 9573594
    [No Abstract]   [Full Text] [Related]  

  • 30. [Echinocandins: searching for differences. The example of their use in patients requiring continuous renal replacement therapy].
    de la Llama-Celis N; Huarte-Lacunza R; Gómez-Baraza C; Cañamares-Orbis I; Sebastián-Aldeanueva M; Arrieta-Navarro R
    Rev Esp Quimioter; 2012 Dec; 25(4):240-4. PubMed ID: 23303253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.
    Keller E; Reetze P; Schollmeyer P
    Clin Pharmacokinet; 1990 Feb; 18(2):104-17. PubMed ID: 2180611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous renal replacement therapies: an update.
    Manns M; Sigler MH; Teehan BP
    Am J Kidney Dis; 1998 Aug; 32(2):185-207. PubMed ID: 9708602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.
    Pistolesi V; Morabito S; Di Mario F; Regolisti G; Cantarelli C; Fiaccadori E
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applying pharmacokinetic/pharmacodynamic principles for optimizing antimicrobial therapy during continuous renal replacement therapy.
    Honore PM; Jacobs R; De Waele E; Spapen HD
    Anaesthesiol Intensive Ther; 2017; 49(5):412-418. PubMed ID: 29171000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy.
    Lewis SJ; Switaj LA; Mueller BA
    Blood Purif; 2015; 40(1):66-71. PubMed ID: 26138225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drugs dosing in intensive care unit during continuous renal replacement therapy].
    Bourquin V; Ponte B; Saudan P; Martin PY
    Nephrol Ther; 2009 Nov; 5(6):533-41. PubMed ID: 19369134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acetaminophen clearance during ex vivo continuous renal replacement therapies.
    Scoville BA; Vulaj V; Mueller BA; Annich GM; Wagner DS
    J Artif Organs; 2018 Jun; 21(2):215-219. PubMed ID: 29063343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
    Bouchard J; Ghannoum M; Bernier-Jean A; Williamson D; Kershaw G; Weatherburn C; Eris JM; Tran H; Patel JP; Roberts DM
    Clin Toxicol (Phila); 2015 Mar; 53(3):156-63. PubMed ID: 25661675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic aspects of continuous renal replacement therapies.
    Druml W
    Kidney Int Suppl; 1999 Nov; (72):S56-61. PubMed ID: 10560807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Actually delivered dose of continuous renal replacement therapy is underestimated in hemofiltration.
    Zhang Z; Ni H; Fan H; Li D; Xu X
    ASAIO J; 2013; 59(6):622-6. PubMed ID: 24172268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.